Samuel Sears

Directeur/Membre du Conseil chez HEDGEPATH PHARMACEUTICALS INC Fortune : 102 363 $ au 30/06/2026

Profil

Currently, Samuel P.
Sears serves as Independent Director at Inhibitor Therapeutics, Inc. since 2022 and as Of Counsel at Cetrulo & Capone LLP since 2019.
Formerly, the roles include Chairman & Chief Executive Officer at Rock Creek Pharmaceuticals, Inc. in 1998, Vice Chairman at American Prescription Providers, Inc. in 1999, Director at Independent Bank Corp.
(Michigan), Independent Director at Commonwealth Biotechnologies, Inc. from 2011 to 2013, Independent Director at BioDelivery Sciences International, Inc. from 2011 to 2018, Director at The Casual Male, Inc., Independent Director at Inhibitor Therapeutics, Inc. from 2013 to 2016, and Managing Partner at Burns & Levinson LLP from 1981 to 1993.
Education includes graduate studies at Boston College Law School and undergraduate studies at Harvard College.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
INHIBITOR THERAPEUTICS INC. 0,74 %	01/04/2025	1 279 543 ( 0,74 % )	102 363 $	30/06/2026

Postes actifs de Samuel Sears

Sociétés	Poste	Début
HEDGEPATH PHARMACEUTICALS INC	Directeur/Membre du Conseil	13/12/2022
Cetrulo & Capone LLP	Conseiller Juridique Général	01/01/2019

Anciens postes connus de Samuel Sears

Sociétés	Poste	Fin
BIODELIVERY SCIENCES INTERNATIONAL, INC.	Directeur/Membre du Conseil	21/05/2018
HEDGEPATH PHARMACEUTICALS INC	Directeur/Membre du Conseil	30/11/2016
Commonwealth Biotechnologies, Inc.	Directeur/Membre du Conseil	19/08/2013
American Prescription Providers, Inc.	Directeur/Membre du Conseil	01/02/1999
ROCK CREEK PHARMACEUTICALS, INC.	Directeur Général	01/05/1998